Tyrosine kinase inhibitor (TKI) drugs have revolutionised the treatment of many cancers and TKIs such as gefitinib, erlotinib, and lapatinib that inhibit the EGFR are effective agents in the treatment of certain cancers. This evidence concerns the gene EGFR and cancer.